March 02, 2026 — 4 articles reviewed
This cycle’s dominant themes center on the clinical consequences of high-potency cannabis use, the legislative momentum toward integrating cannabis into hospital settings, and the growing conversation around cannabinoids as alternatives to opioid analgesia. Taken together, these stories reflect a field maturing rapidly on multiple fronts, with both promise and caution warranting physician attention.
🤢 Cannabis Hyperemesis Syndrome: A Diagnosis That Demands Recognition
A 2025 study documenting 4.4 emergency department visits per 100,000 population attributable to CHS underscores that this syndrome is no longer a clinical curiosity but a genuine public health concern. The rise in cases tracks closely with the increasing potency of commercially available THC products and the prevalence of daily, heavy-use patterns. Clinicians evaluating refractory cyclic vomiting should place CHS squarely in their differential, especially when patients report regular cannabis use, as misdiagnosis frequently leads to costly and unnecessary diagnostic workups. The only evidence-based cure remains complete cannabis cessation, though many patients find this intervention difficult once dependence is established. Early recognition and honest, nonjudgmental counseling are the most impactful tools we have right now.
- #78Cannabis Hyperemesis Syndrome cases rise nationwide as providers warn of growing …
🏥 Hospital Cannabis Access: Legislation Moves Forward Across States
Multiple states are advancing bills that would permit cannabis use by patients in hospital settings, signaling a shift in how policymakers view cannabinoid therapy within acute care. If enacted, these measures could expand options for inpatient symptom management, particularly for pain, nausea, and anxiety, while potentially reducing opioid reliance in vulnerable populations. The practical challenge ahead is enormous: hospitals will need robust clinical guidelines, staff education, and clear protocols for administration, dosing, and documentation. This is not theoretical anymore. Health systems should begin planning now so they are not caught unprepared when regulations take effect.
- #72Bills on cannabis use in hospitals advance in several states (Newsletter: March 2, 2026)
🏈 Athletes, Opioids, and the Case for Cannabinoid Analgesia
NFL players publicly reconsidering traditional painkillers in favor of cannabis has brought renewed attention to the pharmacological distinction between opioid receptor binding and endocannabinoid system modulation. Delta-9-THC acts through CB1 and CB2 receptors rather than mu-opioid pathways, offering a mechanistically different analgesic profile with theoretically lower risks of respiratory depression and fatal overdose. However, athlete endorsement is not clinical evidence, and we still lack rigorous head-to-head trial data comparing cannabis-based analgesia to standard pain protocols for musculoskeletal injury. The conversation is valuable because it normalizes a discussion that many patients are already having quietly with their physicians. What we need next is controlled research establishing dosing standards, efficacy thresholds, and long-term safety in well-defined patient populations.
- #65Why Steelers And Other NFL Players Are Reconsidering Traditional Painkillers
🌍 International Market Development: Switzerland’s Integrated Cannabis Platform
Switzerland’s launch of what is described as its first integrated medical cannabis marketplace reflects the broader global trend of building infrastructure to support regulated cannabinoid prescribing. While the announcement itself is light on clinical data, the development matters because market integration tends to improve supply chain consistency, product standardization, and data collection over time. For clinicians, the takeaway is that international frameworks are evolving in ways that may eventually yield better-quality real-world evidence from well-regulated systems. We should watch these models closely for lessons that could inform domestic policy and clinical practice.
- #45Evidena Care Launches Switzerland’s First Integrated Medical Cannabis Market …
This batch of news captures the tension at the heart of cannabis medicine right now: expanding access and growing acceptance are outpacing the controlled evidence base we need to guide safe, effective care. Our job as clinicians is to stay engaged with both the promise and the risk, and to insist that policy, practice, and science move forward together.